Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin

The luteinizing hormone-releasing hormone/androgen receptor (LHRH/AR) pathway is a promising treatment target in a subgroup of female patients with triple-negative breast cancer (TNBC). However, very little is known about the efficacy of this strategy in male patients with TNBC. In this report, we d...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdel Azim, Hamdy, Kassem, Loay, Shohdy, Kyrillus Samaan, Eshaak, Boules, Anis, Shady Elia, Kamal, Nermine Shawky
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438837/
https://www.ncbi.nlm.nih.gov/pubmed/30941241
http://dx.doi.org/10.4048/jbc.2019.22.e2
Descripción
Sumario:The luteinizing hormone-releasing hormone/androgen receptor (LHRH/AR) pathway is a promising treatment target in a subgroup of female patients with triple-negative breast cancer (TNBC). However, very little is known about the efficacy of this strategy in male patients with TNBC. In this report, we describe a male patient with AR-positive TNBC who was successfully treated using an LHRH agonist after pretreatment with several lines of chemotherapy and achieved a durable response. We also review the existing evidence supporting LHRH- and AR-targeted therapy for this rare disease.

Ejemplares similares